With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.
【JPMA / NCBN】
Joint research between industry-academia-government to create new drugs-Building an integrated database of disease-specific information
January 27th, 2021
Seven member companies of the Japan Pharmaceutical Manufacturers Association (JPMA) and the National Center Biobank Network (NCBN) announced on December 25 that they will start joint research on building and utilizing an integrated database of disease-specific information that is expected to be used in developing new drugs and personalized medicine. The joint research is carried out until March 2025. After obtaining omics data such as genetic information and protein from patient-derived samples attached to clinical information held by NCBN, industry-academia-government jointly builds an integrated database of disease-specific information by combining analysis results with clinical information such as laboratory data and image data.
(Continue to the next)
For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.